The kinetics of hepatitis C virus infection

Clinics in Liver Disease

Volumn 5, Issue 4, 2001, Pages 917-930

  Zeuzem, Stefan ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; RIBAVIRIN;

DOSE RESPONSE; HALF LIFE TIME; HEPATITIS C; HUMAN; KINETICS; LIVER CELL; MATHEMATICAL MODEL; NONHUMAN; REVIEW; VIREMIA; VIRION; VIRUS LOAD;

EID: 0034783406     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(05)70201-4     Document Type: Article

References (55)

1. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon α-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC)
2. Time course of interferon levels, antiviral state, 2′,5′-oligoadenylate synthetase and side effects in healthy men
3. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy
4. Viral kinetics
5. Influence of ribavirin on the dynamics of hepatitis C viremia in interferon-α treated patients with response or nonresponse
6. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial
7. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease
8. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin
9. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
10. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
11. A pilot study of ribavirin therapy for chronic hepatitis C
12. Viral dynamics of hepatitis C early after orthotopic liver transplantation: Evidence for rapid turnover of serum virions
13. Biochemistry and clinical applications of ribavirin
14. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data
15. Cytokine-mediated control of viral infections
16. To kill or to cure: Options in host defense against viral infection
17. Broadly reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: Relation to viral loads and response to interferon
18. Hepatitis C virus kinetics
19. Viral dynamics in vivo: Limitations on estimates of intracellular delay and virus decay
20. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
21. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus
22. Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 Week treatment analysis of a multicenter, multinational phase III randomized controlled trial
23. Dynamics of hepatitis C viremia after plasma exchange
24. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
25. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b and genotype 2c infected patients
26. Antibody responses to hepatitis C virus hypervariable region 1: Evidence for cross-reactivity and immune-mediated sequence variation
27. Early prediction and mechanism of the ribavirin/IFN-α dual therapy effect on chronic hepatitis C virus (HCV)
28. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus
29. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
30. Rapid viral response to treatment with pegylated (40kDa) interferon alfa-2a (Pegasys™) is strongly predictive of a sustained virologic response in patients with chronic hepatitis C (CHC)
31. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection
32. Viral dynamics in hepatitis B virus infection
33. The therapeutic value of poly(ethylene glycol)-modified proteins
34. Standardization of hepatitis C virus RNA quantification
35. Effect of intermittent interferon (IFN), daily IFN and IFN plus ribavirin induction therapy on hepatitis C virus (HCV) genotype 1b replication kinetics and clearance
36. Hepatitis C virus (HCV) dynamics during induction therapy with interferon (IFN) alpha and/or ribavirin
37. Hepatitis C virus resistance to antiviral therapy
38. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
39. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis
40. Interferons, nucleoside analogs and their actions
41. Use of high-dose interferon in the treatment of chronic hepatitis C
42. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta
43. Prediction of early viral clearance with daily IFN + RIB using a mathematical model
44. How cells respond to interferons
45. New insights into the mechanisms of interferon alfa: An immunoregulatory and anti-inflammatory cytokine
46. Pegylated interferon alfa-2b (PEG-Intron) monotherapy is superior to interferon alfa-2b (Intron A) for the treatment of chronic hepatitis C
47. Clinical pharmacokinetics of interferons
48. Dynamics of hepatitis C viremia following interferon-α administration
49. Humoral immune response to the hypervariable region of hepatitis C virus differs between between genotypes 1b and 2a
50. Peginterferon alfa-2a in patients with chronic hepatitis C
51. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology
52. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a
53. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa
54. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo
55. Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover